BIOLASE, INC: Nasdaq/NYSE listing notice — BIOLASE receives Nasdaq delisting notice for negative equity of -$1.93M

BIOLASE, INC

Nasdaq notified BIOLASE on May 14, 2024 that stockholders' equity of ($1.93M) fails minimum $2.5M requirement.
This is an additional basis for delisting and will be considered by the Nasdaq Hearings Panel.
Company has requested a hearing before the Panel, scheduled for June 2024.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIOLASE, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

May 14, 2024, BIOLASE, Inc. (the “Company”) received an additional staff determination letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC notifying the Company that because its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 that was filed with the U.S. Securities and Exchange Commission on May 13, 2024 reported stockholders’ equity of ($1,934,000) as of March 31, 2024, the Company does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5550(b). As a result

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-24-061330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.